Find clinical trials for Pancreatic Cancer in Valencia, VC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Valencia, VC, ESP:
with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...
Phase 3
Valencia, Spain and 89 other locations
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...
Phase 2
Valencia, Spain and 16 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Valencia, Spain and 65 other locations
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immun...
Phase 2
Valencia, Spain and 64 other locations
with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tol...
Phase 1, Phase 2
Valencia, Spain and 17 other locations
The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given...
Phase 1
Valencia, Comunidad Valenciana, Spain and 19 other locations
consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometri ...
Phase 2
Valencia, Spain and 76 other locations
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinic...
Phase 1
Valencia, Spain and 91 other locations
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated G...
Phase 2
Valencia, Valenciana, Comunitat, Spain and 123 other locations
To assess:efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification,...
Phase 2
Valencia, Spain and 90 other locations
Clinical trials
Research sites
Resources
Legal